Çamci S, Yilmaz E, Yakarişik M
Department of Cardiology, Department of Internal Medicine, Faculty of Medicine, Giresun University, Giresun, Turkey.
Eur Rev Med Pharmacol Sci. 2022 Oct;26(19):7036-7045. doi: 10.26355/eurrev_202210_29887.
In our study, we aimed at evaluating the change in biventricular functions and pulmonary arterial stiffness (PAS) in patients with subclinical hypothyroidism (SH) in whom euthyroidism was achieved with L-thyroxine therapy.
70 SH patients and 75 healthy volunteers were included in our study consecutively. Baseline demographic and echocardiographic data of the participants were recorded. The data obtained in the control evaluation 6 months after the euthyroidism were achieved in the SH group patients started on L-thyroxine treatment and then compared with the baseline measurements.
The mean age of patients in the SH group was 44.1 ± 9.4 years and 47.1% were women. Euthyroidism in SH patients was achieved with a mean daily L-thyroxine treatment of 59 µg/day for a mean of 16.1 ± 4.5 weeks. Positive changes in metabolic and hormonal profiles were achieved after L-thyroxine treatment in SH patients. It was determined that left ventricular and right ventricular isovolumetric relaxation and myocardial performance index were higher in SH patients compared to the control group, and these measurements were observed to decrease significantly with L-thyroxine treatment (p < 0.05 for each). While PAS was 16.9 ± 3.1 kHz/ms in the control group, it was 25.2 ± 5.3 kHz/ms in the SH group (p < 0.05). After L-thyroxine treatment, PAS measurements decreased to 17.2 ± 3.2 kHz/ms (p < 0.05) in the SH group and showed a positive change. Thyroid-stimulating hormone (TSH) change (Δ TSH) with Δ E/A ratio (r: -0.407, p < 0.001), right ventricular myocardial performance index (Δ RV MPI) change (r: 0.404, p < 0.001) and PAS change (Δ PAS) (r: 0.458, p < 0.001) found to be correlated.
SH is associated with dysfunction in the biventricular and pulmonary vascular bed. Biventricular functions and PAS change positively in SH patients with L-thyroxine treatment.
在我们的研究中,我们旨在评估通过左甲状腺素治疗实现甲状腺功能正常的亚临床甲状腺功能减退症(SH)患者的双心室功能和肺动脉僵硬度(PAS)的变化。
我们的研究连续纳入了70例SH患者和75名健康志愿者。记录参与者的基线人口统计学和超声心动图数据。在开始接受左甲状腺素治疗的SH组患者中,在实现甲状腺功能正常6个月后的对照评估中获得数据,然后与基线测量值进行比较。
SH组患者的平均年龄为44.1±9.4岁,女性占47.1%。SH患者通过平均每日59μg/天的左甲状腺素治疗,平均16.1±4.5周实现了甲状腺功能正常。SH患者接受左甲状腺素治疗后,代谢和激素水平出现了积极变化。结果发现,与对照组相比,SH患者的左心室和右心室等容舒张期及心肌性能指数更高,并且观察到这些测量值在接受左甲状腺素治疗后显著降低(每项p<0.05)。对照组的PAS为16.9±3.1kHz/ms,SH组为25.2±5.3kHz/ms(p<0.05)。左甲状腺素治疗后,SH组的PAS测量值降至17.2±3.2kHz/ms(p<0.05),呈现出积极变化。发现促甲状腺激素(TSH)变化(ΔTSH)与ΔE/A比值(r:-0.407,p<0.001)、右心室心肌性能指数(ΔRV MPI)变化(r:0.404,p<0.001)和PAS变化(ΔPAS)(r:0.458,p<0.001)相关。
SH与双心室和肺血管床功能障碍有关。接受左甲状腺素治疗的SH患者的双心室功能和PAS出现积极变化。